AI-Powered, Modular and Hybrid Energy Dual Hormone Insulin-Glucagon Pump System
Patent Information
- Application Number
- TR202606343
- Authority / Receiving Office
- TR · TR
- Patent Type
- Applications
- Current Assignee / Owner
- Filing Date
- 2026-04-27
- Publication Date
- 2026-08-21
Smart Images
Figure 00000009_0000 
Figure 00000010_0000 
Figure 00000011_0000
Abstract
Description
TARIFF AI-POWERED, MODULAR AND HYBRID ENERGY PAIR HORMONE-BASED INSULIN-GLUCAGONE PUMP SYSTEM Technical Area The invention enables autonomous monitoring of blood glucose levels in patients with type 1 diabetes and It relates to the organization of; specifically, modular systems that use AI-powered decision algorithms. It has a structure that can operate with hybrid energy harvesting and produces both insulin and glucagon hormones. It involves a dual hormone drug pump system that can be administered. State of the Art Known continuous glucose monitoring (CGM) systems used in diabetes management utilize subcutaneous sensors. It measures glucose levels periodically through this device; insulin pumps, on the other hand, provide basal and bolus glucose. It provides insulin infusion. Closed-loop systems (artificial insulin) combine these two technologies. (pancreas) is also known. A common limitation of known systems is that they are monolithic and disposable, therefore each It means that the entire device turns into electronic waste during its usage period. Also known as... Most systems only deliver insulin, which is vital during hypoglycemia. It is unable to regulate the glucagon hormone. Known alarm mechanisms are reactive and threshold-based. It works by taking contextual data such as the user's movement or sleep status into account. It does not take place. Finally, in known systems, in cases where the user loses consciousness... There is no autonomous emergency call mechanism in place to activate. Purpose of the Invention The aim of the invention is to create a permanent electronic capsule that overcomes the limitations mentioned above. It consists of a biohormone pump unit that is periodically replaced, thus electronically The goal is to offer a system that reduces the amount of waste. Another aim of the invention is to combine glucose change acceleration (Δ²G) and user movement data. by assessing and predicting the risk of hypoglycemia, and autonomously when necessary. The goal is to provide a contextual AI module that triggers glucagon release. 1 / 13 Another purpose of the invention is to provide a solution in cases of critical hypoglycemia where no response is obtained from the user. A security system that autonomously calls an emergency center and transmits location and health data. The goal is to provide the module. Another aim of the invention is a hybrid energy harvester that generates energy from solar power and body heat. The aim of this unit is to reduce the user's need to frequently charge the device. Explaining the Figures: Figure 1: General perspective view of the system (Electronic Capsule (1) and Pump Unit (2)) (shown together) Figure 2: Exploded Permanent Electronic Capsule (1) and Biohormone Pump Unit (2) (separated) appearance Figure 3: Cross-sectional view of the dual reservoir drug reservoir (8) and cannula (9). Figure 4: Flowchart of the Autonomous Emergency Module (13) (steps 101-104) Explanation of Reference Symbols 1: Permanent electronic capsule (brain unit) 2: Biohormone pump unit (consumable module) 3: Artificial intelligence processor (low-power local / edge processor) 4: Wireless communication module (low-energy short-range wireless communication unit) 5: Rechargeable battery 6: Flexible solar cells 7: Thermoelectric Generator (TEG) 8: Dual reservoir medicine dispenser 8a: Insulin reservoir 8b: Glucagon reservoir 9: Flexible cannula 10: Adhesive base layer that comes into contact with the skin. 11: Automatic applicator mechanism 2 / 13 12: Artificial intelligence algorithm module 13: Autonomous emergency module 14: GPS module 15: Image processing module 16: Glucose sensor 17: Accelerometer (IMU) 101: Determining the critical glucose threshold step 102: Step for providing audible / vibrational warning 103: User response evaluation step 104: Step to initiate an autonomous emergency call. Description of the Invention The system described in the invention consists of two main modules that are functionally separable: one permanent electronic capsule (1) and a biohormone pump attached to it in a removable manner. unit (2). Permanent electronic capsule (1) is designed for a lifespan of 3-6 months; inside is an artificial intelligence processor (3), a wireless communication module (4) and a rechargeable It contains a battery (5). Flexible solar cells (6) are positioned on the upper surface of the permanent electronic capsule (1). a thermoelectric generator (7) that produces energy from the difference between body temperature and ambient temperature, Together they form a hybrid energy harvesting unit. In this way, the battery (5), user It can be powered by electricity without needing frequent charging. The biohormone pump unit (2) has a lifespan of 14 days and delivers insulin and glucagon. A dual reservoir medicine dispenser (8) containing separate reservoirs (8a, 8b) for the user a flexible cannula (9) placed in the skin, a hydrocolloid-based adhesive that comes into contact with the skin a spring-loaded applicator that precisely places the base layer (10) and cannula (9) into the skin It includes mechanism (11). The AI algorithm module (12) that runs on the AI processor (3) is a glucose first derivative (ΔG) and second derivative of the glucose level taken from the sensor (16) with respect to time (Δ²G) is calculated in real time. The Δ²G value indicates how fast the glucose rate is changing. It indicates that changes are occurring, allowing for earlier detection of sudden rises or falls. 3 / 13 The artificial intelligence algorithm module (12) provides this data obtained from an accelerometer (17). By combining user activity data (walking, running, resting, sleeping), the risk of hypoglycemia is determined. It can predict a predetermined time in advance and, if necessary, activate the autonomous emergency module. (13) triggers autonomous glucagon release from the biohormone pump unit (2). The system also analyzes photos of the food the user consumes to determine carbohydrate levels. a deep learning-based image processing module that enables the estimation of the amount (15) It includes the prediction produced by this module, the artificial intelligence algorithm module (12) This information is transmitted as input for insulin dose calculation. The working principle of the autonomous emergency module (13) is as follows: glucose level in advance the detection that it has fallen below a predetermined critical threshold (101), followed by the previously giving an audible and vibrating warning for a specified period of time (102), during which time (103) evaluating whether a response has been received from the user and if no response has been received, the user with location information obtained through a location determination module (14) A data packet containing identification information and recent glucose history is transmitted via wireless communication. Through module (4), autonomous emergency call center via emergency call communication infrastructure. It consists of (104) steps for transmission. The wireless communication module (4) can receive the surrounding internet connection when there is no internet connection. node-to-node transfer, enabling data transmission over other compatible devices. It also supports a short-range wireless network (mesh network) structure capable of doing so; thus The functionality of the autonomous emergency module (13) is also available in areas without internet access. It is sustainable. How the invention can be applied to industry. This invention is primarily applicable to the medical devices and biomedical technology sectors. The invention... The way it is applied to industry is as follows: Production: The invention can be mass-produced by companies experienced in the manufacture of medical devices. Separate for Permanent Electronic Capsule (1) and Replaceable Biohormone Pump Unit (2) Production lines can be established for high volume and low cost production of consumable modules (2). Plastic injection and micro-pump technologies can be utilized. Area of Application: The invention is intended for use in patients with type 1 diabetes, as well as those with advanced type 2 diabetes. It can also be used in patients. The device will become an integral part of the patient's daily life. It is designed in this way. In addition, the developed artificial intelligence algorithm module (12) and autonomous emergency 4 / 13 Status module (13), wearable technologies to be used in monitoring other chronic diseases It can also be a source of inspiration. Commercialization: After obtaining approval from the Turkish Ministry of Health's Medicines and Medical Devices Agency (TİTCK), the invention can be distributed through pharmacies and other markets. Medical products can be marketed through sales points. Additionally, in cooperation with the Ministry of Health... The aim of the upcoming negotiations is to have the product included in the Social Security Institution's reimbursement coverage. Modular Thanks to its design, the device can be sold as a regular consumable without high initial costs. It can be commercialized with this model. The domestic production potential represents Türkiye's export potential in this field. This allows it to reduce dependence and become a value-added export product. 5 / 13
Claims
REQUIREMENTS 5 1. Monitoring and regulating blood sugar levels in patients with type 1 diabetes. It is an insulin-glucagon pump system with the following features: — containing an artificial intelligence processor (3), a wireless communication module (4) and a removable / attachable permanent electronic device housing a rechargeable battery (5) capsule (1), 10 — insulin and glucagon detached from a permanent electronic capsule (1) It has a dual reservoir medicine chamber (8) with separate reservoirs (8a, 8b) for, a periodically replaceable biohormone pump unit (2), — Simultaneously monitors glucose change acceleration (Δ²G) and user movement data. by processing and predicting the risk of hypoglycemia, and biohormones when needed. an artificial intelligence that triggers autonomous glucagon release from the pump unit (2) algorithm module (12), — the user's glucose level falls below the critical threshold and 20% of the user If no response is received within the expected time frame, an emergency call is automatically triggered. an autonomous emergency module (13) that calls its center, It includes.
2. The pump system according to claim 1 is characterized by being on the permanent electronic capsule (1). 25 positioned, flexible solar cells that convert light energy into electrical energy (6) and a thermoelectric that produces energy from the difference between body temperature and ambient temperature. It has a hybrid energy harvesting unit which includes a generator (7).
3. The pump system according to claim 1 is characterized by its artificial intelligence algorithm module (12), glucose by calculating the first derivative (ΔG) and the second derivative (Δ²G) of the level with respect to time 30 It is structured.
4. The pump system according to claim 1 is characterized by; biohormone pump unit (2), hydrocolloid that comes into contact with the skin via a flexible cannula (9) placed on the user's skin It contains a basic, breathable adhesive base layer (10). 6 / 13 5. Pump system according to claim 4, its feature is; biohormone pump unit (2), cannula (9) 5 It includes a spring-loaded applicator mechanism (11) that automatically places it on the skin.
6. The pump system is in accordance with claim 1 and its feature is that the autonomous emergency module (13) is critical When the glucose threshold is detected, it provides an audible and vibrating alert for a predicted duration. If no response is received within the specified time, a location determination module (14) will be used. A 10-bit document containing specified location information, user credentials, and glucose history. will transmit the data packet to the emergency call center via the wireless communication module (4) It is structured in this way.
7. According to claim 1, it is a pump system whose feature is; the food consumed by the user By analyzing photographs, it is possible to estimate the amount of carbohydrates. It includes a deep learning-based image processing module (15) and obtains 15 from this module. The prediction is transferred as input to the artificial intelligence algorithm module (12).
8. Pump system according to claim 1, its feature is; wireless communication module (4), internet In situations where a connection is not available, the node can be accessed via other nearby devices. It supports a short-range wireless network structure that enables data transmission to the node.
9. A method for operating an insulin-glucagon pump system, characterized by; 20 —continuous measurement of the user's glucose level, — the first derivative (ΔG) and second derivative (Δ²G) values from the measured glucose level the calculation of their values by an artificial intelligence processor (3), — the calculated Δ²G value with user motion data obtained from an accelerometer merging, 25 —predicting the risk of hypoglycemia from combined data, — Autonomous glucagon when deemed necessary based on the estimated risk. triggering its release, —detection that glucose levels have fallen below the critical threshold, —auditory and vibrating alerts for the foreseen duration, 30 — if no response is received within this period, data including location and health information will be collected. autonomous transmission of the data packet to the emergency call center, It includes the steps. 7 / 13 10. The method according to claim 9 is characterized by; 5 photos of the food consumed by the user. by analyzing and estimating the amount of carbohydrates, and the estimated value This includes the step of using it as an input in insulin dose calculation. 8 / 13